Order Article Reprints

Kocaaslan E, Güren AK, Akagündüz F, Demirel A, Tunç MA, Paçacı B, Ağyol Y, Erel P, Çelebi A, Işık S, et al. Prognostic Value of ¹⁸F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine. 2026; 15(2):798. https://doi.org/10.3390/jcm15020798

Kocaaslan, Erkam, Ali Kaan Güren, Fırat Akagündüz, Ahmet Demirel, Mustafa Alperen Tunç, Burak Paçacı, Yeşim Ağyol, Pınar Erel, Abdüssamed Çelebi, Selver Işık, and et al. 2026. "Prognostic Value of ¹⁸F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab" Journal of Clinical Medicine 15, no. 2: 798. https://doi.org/10.3390/jcm15020798

Kocaaslan, E., Güren, A. K., Akagündüz, F., Demirel, A., Tunç, M. A., Paçacı, B., Ağyol, Y., Erel, P., Çelebi, A., Işık, S., Çoban, E., Demircan, N. C., Özgüven, S., Balaban Genç, Z. C., Majidova, N., Sever, N., Sarı, M., Köstek, O., & Bayoğlu, I. V. (2026). Prognostic Value of ¹⁸F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine, 15(2), 798. https://doi.org/10.3390/jcm15020798